GSTM1 Deletion Compensated in mRNA Expression and 4T1 Viability After Editing Using CRISPR/Cas9 Single and Double gRNA
Abstract
BACKGROUND: Glutathione S-transferase Mu-1 (GSTM1) is known to undergo polymorphism and plays role in drug metabolism including Paclitaxel (PTX), the first-line chemotherapy for breast cancer. However, the effect of GSTM1 polymorphism against chemotherapy in breast cancer is limited and unexplored. This study was conducted to explore the effects of single and double guide (gRNA) on the GSTM1 knocked out (KO) and its effect on the response of PTX in the 4T1 cell line.
METHODS: The preparatory stage was done by culturing and electroporating 4T1 cells using Ribonucleoprotein of clustered regularly interspaced short palindromic repeats (CRISPR)/Caspase 9 (Cas9). KO validation was examined by quantitative reverse transcription polymerase chain reaction (qRT-PCR), Sanger sequencing, and ICE analysis. The 4T1 viability was examined by MTT Assay.
RESULTS: The number of base pairs of GSTM1 after being engineered by single or double gRNA was 86 bases. The DNA quantity of GSTM1 engineered by gRNA was more than using double gRNAs. The mRNA expression of GSTM1 engineered by single gRNA was lower than using double gRNAs. IC50 values of PTX between wildtype and KO were not significantly different, in the range of 30 µM.
CONCLUSION: The base-pair length of GSTM1 exon 4 that is knocked out with single and double gRNA have the same number of base pairs. The quantity of GSTM1 DNA and mRNA expression are contrary between single gRNA and double gRNA, and IC50 PTX values in the 4T1 cell line of the control group with single or double gRNA knocked out do not differ markedly. PTX efficiency as chemotherapy is not disturbed in the GSTM1 deletion genetic profile.
KEYWORDS: GSTM1, gRNA, Paclitaxel, CRISPR, breast cancer
Full Text:
PDFReferences
Arakawa S. Utilization of glutathione S-transferase Mu 1- and Theta 1-null mice as animal models for absorption, distribution, metabolism, excretion and toxicity studies. Expert Opin Drug MetabToxicol. 2013; 9(6): 725-36, CrossRef.
Singh S, Joshi B, Saini A, Mohapatra T. Smoking, glutathione S transferase polymorphisms (GSTM1 & GSTT1) and their association with selected inflammatory biomarkers. Al Ameen J Med Sci. 2022; 15(2): 113-22, article.
Němcová-Fürstová V, Kopperová D, Balušíková K, Ehrlichová M, Brynychová V, Václavíková R, et al. Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters. Toxicol Appl Pharmacol. 2016; 310: 215-28, CrossRef.
Abdihalim TS, Idris AAA. Mucin level as a potential biomarker for breast cancer diagnosis. Mol Cell Biomed Sci. 2022; 6(3): 117-20, CrossRef.
Pacholak LM, Kern R, de Oliveira ST, Lúcio LC, Amarante MK, Guembarovski RL, et al. Effects of GSTT1 and GSTM1 polymorphisms in glutathione levels and breast cancer development in Brazilian patients. Mol Biol Rep. 2021; 48(1): 33-40, CrossRef.
Widowati W, Jasapura DK, Sumitro SB, Widodo MA, Afifah E, Rizal R, et al. Direct and indirect effect of TNFα and IFNγ toward apoptosis in breast cancer cells. Mol Cell Biomed Sci. 2018; 2(2): 60-9, CrossRef.
Gote V, Sharma AD, Pal D. Hyaluronic acid-targeted stimuli-sensitive nanomicelles co-encapsulating paclitaxel and ritonavir to overcome multi-drug resistance in metastatic breast cancer and triple-negative breast cancer cells. Int J Mol Sci. 2021; 22(3): 1-31, CrossRef.
Ali A, Ali A, Ahmad S. Alterations of glutathione and GSTM1 mutation induce tumor metastasis and invasion via EMT pathway in breast cancer patients. EJMO. 2021; 5(3): 249-59, CrossRef.
Meiliana A, Dewi NM, Wijaya A. Personalized medicine: The future of health care. Indones Biomed J. 2016; 8(3): 127-46, CrossRef.
Aborehab NM, Elnagar MR, Waly NE. Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2020; 35(2): 1-11, CrossRef.
Yamaguchi H, Hishinuma T, Endo N, Tsukamoto H, Kishikawa Y, Sato M, et al. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int J Gynecol Cancer. 2006; 16(3): 979-85, CrossRef.
Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, et al. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci. 2015; 106(1): 86-93, CrossRef.
Meiliana A, Dewi NM, Wijaya A. Genome editing with CRISPR-Cas9 system: Basic research and clinical applications. Indones Biomed J. 2017; 9(1): 1-16, CrossRef.
Haghighi N, Doosti A, Kiani J. Evaluation of CRISPR/Cas9 system effects on knocking out NEAT1 gene in AGS gastric cancer cell line with therapeutic perspective. J Gastrointest Cancer. 2022; 53(3): 623-31, CrossRef.
Abdollah NA, Safiai NIM, Ahmad MK, Das KT, Razak SRA. Suppresion of MiR130a-3p using CRISPR/Cas9 induceds proliferation and migration of non-small cell lung cancer cell line. Indones Biomed J. 2021; 13(4): 364-74, CrossRef.
Nugrahaningsih DAA, Purnomo E, Wasityasuti W, Martien R, Arfian N, Hartatik T. BMPR2 editing in fibroblast NIH3T3 using CRISPR/Cas9 affecting BMPR2 mRNA expression and proliferation. Indones Biomed J. 2021; 14(1): 45-51, CrossRef.
Varan G, Varan C, Ozturk SC, Benito, JM, Esendagli G, Bilensoy E. Therapeutic efficacy and biodistribution of paclitaxel-bound amphiphilic cyclodextrin nanoparticles: analyses in 3D tumor culture and tumor-bearing animals in vivo. Nanomaterials. 2021; 11(2): 515, CrossRef.
Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, et al. Cell viability assays. In: Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin C, et al, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004, NLMID.
Corsi GI, Qu K, Alkan F, Pan X, Luo Y, Gorodkin J. CRISPR/Cas9 gRNA activity depends on free energy changes and on the target PAM context. Nat Commun. 2022; 13(1): 3006, CrossRef.
Giuliano CJ, Lin A, Girish V, Sheltzer JM. Generating single cell-derived knockout clones in mammalian cells with CRISPR/Cas9. CurrProtoc Mol Biol. 2019; 128(1): e100, CrossRef.
López-Manzaneda S, Ojeda-Pérez I, Zabaleta N, García-Torralba A, Alberquilla O, Torres R, et al. In vitro and in vivo genetic disease modeling via NHEJ-precise deletions using CRISPR-Cas9. Mol Ther Methods Clin Dev. 2020; 19: 426-37, CrossRef.
Chen D, Tang JX, Li B, Hou L, Wang X, Kang L. CRISPR/Cas9-mediated genome editing induces exon skipping by complete or stochastic altering splicing in the migratory locust. BMC Biotechnol. 2018; 18(1): 60, CrossRef.
Kaneko T, Sakuma T, Yamamoto T,Mashimo, T. Simple knockout by electroporation of engineered endonucleases into intact rat embryos. Sci Rep. 2014; 4: 6382, CrossRef.
Iwata S, Nakadai H, Fukushi D, Jose M, Nagahara M, Iwamoto T. Simple and large-scale chromosomal engineering of mouse zygotes via in vitro and in vivo electroporation. Sci Rep. 2019; 9(1): 14713, CrossRef.
Isaac RS, Jiang F, Doudna JA, Lim WA, Narlikar GJ, Almeida R. Nucleosome breathing and remodeling constrain CRISPR-Cas9 function. Elife. 2016; 28(5): e13450, CrossRef.
Doll NM, Gilles LM, Gérentes MF, Richard C, Just J, Fierlej Y, et al. Single and multiple gene knockouts by CRISPR-Cas9 in maize. Plant Cell Rep. 2019; 38(4): 487-501, CrossRef.
Ren F, Ren C, Zhang Z, Duan W, Lecourieux D, Li S, et al. Efficiency optimization of CRISPR/Cas9-mediated targeted mutagenesis in Grape. Front Plant Sci. 2019; 10: 612, CrossRef.
Zhang XH, Tee LY, Wang XG, Huang QS, Yang SH. Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol Ther Nucleic Acids. 2015; 4(11): e264, CrossRef.
Bhattacharjee P, Paul S, Banerjee M, Patra D, Banerjee P, Ghoshal N, et al. Functional compensation of glutathione S-transferase M1 (GSTM1) null by another GST superfamily member, GSTM2. Sci Rep. 2013; 3: 2704, CrossRef.
Yu KD, Fan L, Di GH, Yuan WT, Zheng Y, Huang W, et al. Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1. Breast Cancer Res Treat. 2010; 121(2): 485-96, CrossRef.
Nissar S, Sameer A S, Rasool R, Chowdri N A, Rashid F. Glutathione S transferases: Biochemistry, polymorphism and role in colorectal carcinogenesis. J Carcinog Mutagen. 2017; 8(2): 2-9, CrossRef.
de Oliveira AL, Santos RED, Rodrigues FFO. Chemotherapy and mechanisms of resistance in breast cancer. In: Bathe OF, editor. Neoadjuvant Chemotherapy - Current Applications in Clinical Practice. London: IntechOpen Limited; 2012, CrossRef.
DOI: https://doi.org/10.18585/inabj.v15i2.2131
Copyright (c) 2023 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
